drugset / Trial / NCT00914641

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641

Phase 1 Completed 16 enrolled Pfizer Bristol-Myers Squibb · collab
RandomizedCrossoverOpen-labelBasic science

Summary

To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet

Timeline

Start
2009-06
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 10 mg

Indications